New plasma therapy tested in fight against deadly sepsis complications

NCT ID NCT04580563

Summary

This study tested whether a special, standardized plasma product (OctaplasLG®) could help control dangerous blood clotting problems in patients with septic shock. It compared the plasma treatment to a saline placebo in 60 critically ill adults. The main goal was to see if it was practical to give this treatment quickly after diagnosing the clotting issue.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hôpitaux Universitaires de Strasbourg

    Strasbourg, 67000, France

Conditions

Explore the condition pages connected to this study.